I am a biostatistician, working with statistical methods for cancer epidemiology. My main research interest is cancer patient survival and I have published high impact studies on cancer patient survival for a range of cancer sites. I develop statistical methods as well as apply the methods to register-based data to answer important epidemiological and clinical research questions. I believe that an important task for biostatisticians is to communicate the results from complicated statistical methods in a way that is understandable for other researchers, clinicians and healthcare policymakers. Therefore, I put a lot of emphasis on communication and presentation of complex methods in an understandable way. I’m currently working in several projects, a description of two projects I'm heavily involved with currently are described below.

Research description
Survival after hematological cancers, with a focus on MPN I am part of a successful collaborative group of hematologists and biostatisticians at KI. We have been studying the prognosis of a range of hematological malignancies, many of the studies have been published in high-impact journals. I have lately taken a more senior role in the group, and given more responsibility for the research on myeloproliferative neoplasms (MPN), as well as the methods development. Compared to many other hematological malignancies MPNs are rather indolent diseases. Despite efforts to optimize treatment and prophylactic measures, patients with MPNs have a shorter survival than the general population and experience complications, such as thromboembolism and bleedings, due to their MPN. There are few population-based studies on MPNs, and most studies are small with short follow-up time and do not include population controls. It is therefore of great importance to gain a further understanding of the disease trajectory and risk of complications for this group of patients. By taking advantage of the Swedish health registers and novel statistical methods, we will improve the understanding of the clinical course and prognosis among MPN patients.

International Cancer Benchmarking Partnership I am working within a high profile international collaborative project on cancer patient survival, the International Cancer Benchmarking Partnership SURVMARK-2, run by the International Agency for Research on Cancer (IARC) in Lyon in collaboration with renowned experts in the field. The ICBP is an international cancer survival comparison study focused on measuring differences and understanding factors that drive these. I am investigating how much of differences observed in population-based cancer patient survival between countries that is due to differences in reporting to the cancer registries. There are for example differences in the definition of date of diagnosis, definitions and inclusion of multiple primaries and death certificate initiated cases. This is investigated using simulations as well as by analyzing register-based data.